Author
Angelos Moschovakis
Founder of Moschovakis Capital. Quantitative FX automation and institutional equity research. eToro Popular Investor. 24+ months verified track record.
This Meituan stock analysis examines one of the most dramatic collapses in Chinese internet equities during 2025. Meituan (03690.HK), the dominant on-demand services platform…
February 12, 2026 · 15 min read
This Intuit stock analysis identifies one of the most compelling asymmetric opportunities in application software today. INTU trades at $420 — a 50% drawdown…
February 11, 2026 · 13 min read
Mattel stock analysis has become the most searched equity research topic in the consumer discretionary sector this week, and for good reason. On February…
February 11, 2026 · 12 min read
This Moody’s stock analysis identifies one of the most compelling asymmetric opportunities in financial data and analytics for wealth preservation-focused investors. MCO currently trades…
February 10, 2026 · 11 min read
Executive Summary BOTTOM LINE UP FRONT Metric Value Recommendation BUY at €5.97 Fair Value (Base Case) €7.15 Margin of Safety 19.7% Dividend Yield ~6.0%…
February 9, 2026 · 10 min read
Tencent stock analysis is at the forefront of institutional conviction in Chinese technology for 2026. At Moschovakis Capital, our proprietary equity research framework has…
February 9, 2026 · 15 min read
This LSEG stock analysis examines London Stock Exchange Group plc (LON: LSEG) following a severe AI-fear-driven selloff that has created what our proprietary Wealth…
February 9, 2026 · 12 min read
This SMCI stock analysis represents a comprehensive institutional equity research note published by the Moschovakis Capital Wealth Preservation Research Division. Our mandate is capital…
February 7, 2026 · 11 min read
This Doximity stock analysis identifies what we consider one of the most compelling risk-adjusted opportunities in healthcare technology today. At $33.50 per share, DOCS…
February 6, 2026 · 12 min read
This Molina Healthcare stock analysis identifies one of the most compelling asymmetric opportunities in the managed care sector for 2026. At $118 per share…
February 6, 2026 · 14 min read